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d Cartilage 22 (2014) S57–S489Conclusions: The pelvis would appear to remain the optimum site for
harvesting of bone marrow for use in single sitting procedures despite
the increased morbidity from harvesting at this site. Further work is
now being undertaken to establish the properties of MSCs from these
different sites in terms of their ability to differentiate into desired tis-
sues such as cartilage and bone.
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MESENCHYMAL STROMAL CELLS ENCAPSULATION IN INNOVATIVE
BIOMATERIALS: APPLICATION TO OSTEOARTHRITIS TREATMENT
F. Hached y,z, P-G. Pinta y,z, G. Rethore y,z, C. Vinatier y,z, N. Maillard y,
P. Hulin x, P. Weiss y,z, G. Grimandi k,y, J. Guicheux y,z,
A. Billon-Chabaud k,y. y INSERM U791, LIOAD, Group STEP (Skeletal Tissue
Engineering and Physiopathology), Nantes, France; zUFR Odontology,
Nantes, France; x SFR François Bonamy, MicoPICell platform, Nantes,
France; kUFR Pharmacy, Nantes, France
Osteoarthritis (OA) is a very common disease affecting a growing part of
aging population. It is a degenerative joint disease accompanied by
degradation of the articular cartilage and variable degrees of synovium
inﬂammation. Mesenchymal Stromal Cells (MSC) have generated sig-
niﬁcant medical consideration since they secrete immuno-modulatory
and anti-inﬂammatory factors. Unfortunately, the intra-articular injec-
tion of MSC suffers some major limitations including: (i) a massive cell
Abstracts / Osteoarthritis anS444death upon injection in the articular space making difﬁcult to detect the
injected cells for a sustained time; (ii) a risk of cell leak outside the
articular space due to the propensity of MSC to migrate.
Purpose: The present project is devoted to the development of a
therapeutic strategy for OA, based on the exploitation of the immuno-
modulatory properties of MSC. To overcome the limitations of the crude
intraarticular injections (cell death and leakage of MSC), we propose to
entrap bioactive MSC prior to their injection within cytoprotective and
permeable microcapsules made of innovative biomaterials.
Materials: Alginate and silylated hydroxypropyl methylcellulose (Si-
HPMC) were chosen as biocompatible biomaterials able to support the
viability and bioactivity of encapsulated MSC. MSC were isolated from
human adipose tissue (hADSC: human adipose tissue stromal cells).
We selected a dropwise method in CaCl2 solution to obtain alginate
capsules. To produce SI-HPMCmicrocapsules, we developed water in oil
(w/o) emulsion protocol with or without surfactant. To assess pore size
of microcapsules, the diffusion of FITC-dextranmolecules (sizes ranging
from 20 to 2000 KDa) through alginate and Si-HPMC microcapsules
were followed by confocal microscopy. For MSC encapsulation, a hADSC
suspension of 2.106 cells/ml was added either to the alginate solution or
to the Si-HPMC solution (without surfactant). The microbeads were
then collected by ﬁltration, washed with HEPES buffer and seeded in
culture medium. Culture medium was changed every 2 days after cell
encapsulation. hADSC viability after encapsulation in alginate and Si-
HPMC was followed for a period of 24 h to 2 months using a Live/Dead
Viability/Cytotoxicity kit.
Results: By dropwise method, we obtained alginate capsules with an
average size of 1,1 0,2 mm. Preliminary results have shown that their
pore size was between 10 nm and 21 nm.
With Si-HPMC, we managed to develop a suitable microencapsulation
method by varying operating parameters such as surfactant, temper-
ature or rotating speed. In optimal conditions, we obtained Si-HPMC
microbeads with a size of 50,3 4,9 mm (when a surfactant was used)
and 1 0,9 mm (without surfactant). Their pore size was ranging from
10 nm to 21 nm.
Thenwe encapsulated hADSC in both polymers. We detected a high rate
of viable encapsulated cells in 1 mm alginate capsules (about 93% of
viability at 2 months post-encapsulation). In addition, we observed a
lower rate of viable encapsulated hADSC in 1 mm Si-HPMC capsules
(less than 50% of viability at 48 h post-encapsulation).
Conclusions: Alginate and Si-HPMC appear as suitable biomaterials for
producing permeable microcapsules. Dropwise and emulsion methods
allow us to obtain capsules with different sizes. Our data strongly
suggest that capsule porosity is appropriate to maintain cell viability
(diffusion of nutrients and oxygen) and biological functions. Further
experiments are now under investigation to determine whether hADSC
encapsulated in permeable biomaterials may be a relevant strategy to
prevent cartilage degradation and inﬂammation in OA.
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EFFECTS OF TRANSFORMING GROWTH FACTOR b1 ON THE
EXPRESSION OF WNT SIGNALING PATHWAY RELATED GENES IN
THE CHONDROGENIC DIFFERENTIATION OF BONE MARROW
STROMAL STEM CELLS
K. Tao y, H.J. Lin y, H. Zeng z. y Peking Univ. People’s Hosp., Beijing, China;
zDept. of Orthopaedics of Peking Univ. Shenzhen Hosp., Shenzhen, China
Objective: Osteochondral defects is a very common and chanllenging
problem of orthopaedic surgery. The mature chondrocyte embedded in
the avascular (no blood vessels) and aneural (no neurons and nerves)
articular cartilage lacking of usual self-regeneration (the process of
repair by formation of the same type of tissue) after injury or disease.
Stromal stem cells (MSCs) aremultipotent cells and able to differenciate
into chondrocytes under certain culture medium (such as TGF-b, BMPs,
IGFs) and easily proliferate while maintaining their undifferentiated
state. Previous researches have proved that Wnt/b-catenin signaling
pathway is essential for stem cells self-renewal and chondrogenic dif-
ferenciation. In this study, we intend to investigate the transforming
growth factor-b1 (TGF-b1) on expression of Wnt signaling pathway
related genes during the chondrogenesis of bone marrow stem cells
(BMSCs) in vitro.
Methods: The BMSCs of immature SPF SD rat, isolated and cultured
with or without TGF-b1 (2ng/ml TGF-b1 medium containing 10% fetal
bovine serum) in vitro. Cultured cells were observed by inverted phase
contrast microscope and identiﬁed by toluidine blue staining. The
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including wnt1, wnt3a, wnt5a, wnt10b, b-catenin, sox9, runx2, osteo-
pontin, lipoprotein lipase, peroxisome proliferator-activated receptor
gamma (PPAR-g or PPARG), and collagen I, II, X mRNA on different
concentrations of TGF-b1 were detect by ELISA assay and ﬂuorescence
quantitative (FQ)-PCR, respectively.
Results: After cultured in the TGF-b1 medium for 14 days, BMSCs dif-
ferentiated into circular or polygonal cells. After 21 days, 95% of the cells
were circular or polygonal cells with blue secretory granules within the
cytoplasm by toluidine blue staining. Compared with the control group,
the content of GAG increased signiﬁcantly in the group of TGF-b1
medium, especially in 2ng/ml TGF-b1 group by ELISA method. FQ-PCR
results indicated that mRNA expression level of wnt1, wnt3a, wnt5a,
wnt10b and b-catenin after exposure to 2ng/ml TGF-b1 was obviously
suppressed compared with control group, and mRNA expression level
of sox9, collagen II was statistically enhanced, with an results of
inhibiting expression of runx2, osteopontin, lipoprotein lipase, PPAR-g,
and collagen I, X. Moreover, we found that the expression of chondro-
genic related genes was not upon a parallel line with the TGF-b1
concentration.
Conclusion: TGF-b1 can promote BMSCs differentiating into chon-
drocytes. During the differentiation progress, the expression of Wnt/b-
catenin signaling pathway related genes was inhibited and chon-
drocyte speciﬁc genes of sox9, collagen II mRNA were increased. TGF-b
may modulate chondrogenic differenciation though Wnt signaling
pathway.
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CELLS ISOLATED FROM FAT PAD AND SYNOVIAL FLUID. ARE THEY
SUITABLE FOR CARTILAGE REPAIR?
J.K. Garica, C. Mennan, J. Richardson, K. Wright, S. Roberts. Robert Jones
Agnes Hunt Hosp. (Keele Univ.), Oswestry, United Kingdom
Purpose: Autologous Chondrocyte Implantation (ACI) is used as a cel-
lular therapy for treating defects in articular cartilage. Successful ACI
depends on high cell number and quality of the cells which varies
between patients. Alternative cell sources within the joint may provide
a more preferable treatment for OA. The aim of this study is to evaluate
the clinical suitability of infrapatellar fat pad (FP) and synovial ﬂuid (SF)
cells for cartilage repair by determining their MSC-like proﬁle and
response to an inﬂammatory stimulus in vitro.
Methods: Fat pad and synovial ﬂuid were obtained with consent from
the knees of patients undergoing ACI treatment. Cells were isolated
from FP by enzymatic digestion with Collagenase I for 1 h at 37oC fol-
lowed by centrifugation. Synovial ﬂuid cells were obtained by cen-
trifuging the synovial ﬂuid. Resulting cell pellets were seeded onto
tissue culture plastic in DMEM-F12, 10 % FCS and Penicillin/Strepto-
mycin. Expression of cell surface markers was assessed using Flow
cytometry (FACSCanto II). The multipotency of these cells was tested by
culturing in monolayer in osteogenic and adipogenic media. Chondro-
genesis was assessed in 3D pellet culture for 21 days. To evaluate the
immunoresponsive nature of FP and SF cells, the expression of co-
stimulatory markers CD40, CD80, CD86, and Major Histocompatibility
complex II (HLA-DR) was tested before and after stimulation (48 h) with
low (25ng/ml) and high (500ng/ml) concentrations of interferon-g
(IFN-g). Results were compared to those obtained from bone marrow
derived mesenchymal stem cells (BMSCs).
Results: SF and FP cells showed the ability to differentiate down
osteogenic, adipogenic and chondrogenic lineages as shown by positive
alkaline phosphatase (bone), Oil Red O (lipid) and Toluidine blue (gly-
cosaminoglycan) staining.
Cells from both SF and FP were positive for the MSC markers CD73,
CD90, CD105 and negative for HLA-DR. Following stimulation with IFN-
g, both SF and FP cells upregulated CD40 and HLA-DR. In comparison,
BMSCs upregulated HLA-DR after IFN- g stimulation but not the co-
stimulatory marker CD40.
Conclusion: Cells isolated from FP and SF of osteoarthritic joints display
immunogenic properties after stimulation with the pro-inﬂammatory
cytokine IFN-g which may make them unsuitable as alternative cell
sources for ACI. Despite the production of co-stimulatory markers
(CD40) and up regulation of HLA-DR as mentioned above, these cells do
show multipotency via their ability to differentiate down osteogenic,
adipogenic and chondrogenic lineages and they express the MSC
markers CD73, 90 and 105. Their immunoresponsive nature needs to bestudied further before these cells could be considered for routine
applications for cartilage repair.
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DOES MACROPHAGE DEPLETION & CYTOKINE STIMULATION AFFECT
THE PHENOTYPE OF SYNOVIAL MESENCHYMAL PROGENITOR CELLS
IN VITRO?
A. Fichadiya, C. Frank, R. Yates, R. Krawetz. Univ. of Calgary, Calgary, AB,
Canada
Purpose: The aim of the present study was to elucidate the relationship
between synovial mesenchymal progenitor cells (sMPCs) and macro-
phages of the knee joint in OA pathogenesis. Speciﬁcally, this study
sought to assess how components of the macrophage secretome (pro-
and anti-inﬂammatory activation and polarization factors) affect the
chondrogenic capacity of sMPCs in vitro. In addition to this, the effects
of macrophage depletion from OA and normal biopsied human syno-
vium were also assessed.
Methods: Patients with clinical and radiographic OA with no other co-
morbidities consented and had synovial membrane biopsies obtained
during knee arthroplasty or meniscal/ligamentous repair at the Peter
Lougheed Centre, Canada. Synovial ﬂuid and synovial membrane
biopsies from macroscopically normal knees were obtained from
cadavers less the 4 hrs after death. Tissue donors were received by the
Southern Alberta Organ and Tissue Donation Program (SAOTDP). OA
and normal biopsy samples were freshly plated and received 40ng/ml
of IFN-g, TNFa, Il-4, or IL-10, with or without Dichlor-
omethylenediphosphonic acid disodium salt (Clodronate Disodium -
Sigma) in solution every 4 days for 12 days post seeding (clodronate
disodium is a ﬁrst generation bisphosphonate utilized in research for
the depletion of macrophages). Samples of the supernatant are also
collected on days 4, 8, and 12 for proteomic assessment via Luminex.
Following this treated 12 day outgrowth of sMPCs, cells are isolated,
puriﬁed, expanded, and placed in 3 week chondrogenic differentiation
(in pellet culture aggregates). qRT-PCR is conducted thereafter to assess
gene expression levels of chondrogenic factors in addition to qualitative
alcian blue staining.
Results: Our study revealed greater expression levels of Sox9, Col2a and
Aggrecan on sMPCs which came from OA biopsy specimens that
received the clodronate-only treatment in comparison to untreated
biopsy specimens following chondrogenic differentiation. OA Biopsies
which received anti-inﬂammatory cytokines (IL-10 & IL-4) during sMPC
outgrowth also showed greater expression levels of Sox9, Col2a and
Aggrecan following chondrogenic differentiation in comparison to
those receiving pro-inﬂammatory cytokines (IFN-g & TNFa). Addition-
ally, OA biopsies receiving either pro-or anti-inﬂammatory cytokines
alongside clodronate showed variable sMPC expression levels of
chondrogenic factors following differentiation. The TNFa þ Clodronate
group showed the most reduced expression levels in comparison to
sMPCs from untreated biopsies. Normal biopsies which underwent the
same treatment regimens demonstrated similar results in the way of
reduced chondrogenic gene expression following pro-inﬂammatory
exposure, and increased expression following clodronate treatment.
Conclusions: Our ﬁndings shed light on macrophage effects on sMPC
phenotype. Our results demonstrate that depletion of synovial macro-
phages increases the chondrogenic capacity of sMPCs and that pro-
inﬂammatory cytokines which constitute anM1macrophage secretome
